A clinical assessment of lorazepam in the treatment of anxiety associated with gastrointestinal symptomatology.
The effectiveness of lorazepam was assessed under double-blind conditions in 70 ambulant patients suffering from anxiety associated with gastrointestinal symptomatology. In this 4-week study, the usual daily dose of lorazepam, 3.0 mg given in a b.i.d. regimen, produced a greater decrease in symptoms associated with anxiety than placebo at almost all evaluation periods, as indicated by Kruskal-Wallis analyses of Global, Hamilton, and 35-Item ratings--a decrease which was clinically and statistically significant. In addition, lorazepam was well accepted and well tolerated by the majority of patients and was compatible with concomitant medications. Side effects were infrequent and usually controlled by dosage adjustment.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005767:Gastrointestinal Diseases / Q000523:psychology*; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales
D014151:Anti-Anxiety Agents; D010919:Placebos; D008140:Lorazepam